About us

Harnessing our Innovation and Creativity to Make a Valuable Difference to Patients

Scancell is a clinical stage company developing novel active immune-oncology therapies. Our goal is to give patients who have unresponsive tumours an increased chance of survival through durable and potent immune response to checkpoint inhibitors.

Improving patient outcomes underpins our innovation

Immunotherapies have unrivalled efficacy and relatively low toxicity profile compared to chemotherapy and have created a paradigm shift in the treatment of many cancers. However, response rates remain low, with less than 50% of patients typically benefitting from standard of care checkpoint inhibitors (CPIs). Scancell is focused on the development of active immunotherapies from its Immunobody® and Moditope® platforms, which are designed to work synergistically with CPIs, to improve and extend the response rate to CPIs without adding to the burden of toxicity. We aim to provide rapid, effective and scalable solutions for patients with a growing portfolio of off-the-shelf, patient-accessible cancer therapy products.

Phil L'Huillier

Chief Executive Officer

Professor Lindy Durrant

Chief Scientific Officer

Sath Nirmalananthan

Chief Financial Officer, Company Secretary

Dr Nermeen Varawalla

Chief Medical Officer

Dr Mandeep Sehmi

Head of Business Development

Dr Callum Scott

Senior Vice President of Development

Dr Samantha Paston

Head of Translational Research

Dr Shamim Kazmi-Stokes

Head of Programme Management

Philip Angell-Manning

Head of CMC

Alex Hayward

Head of Finance

Phil L'Huillier

Chief Executive Officer

Professor Lindy Durrant

Chief Scientific Officer

Dr Jean-Michel Cosséry

Non-Executive Chairman

Sath Nirmalananthan

Chief Financial Officer, Company Secretary

Martin Diggle

Non-Executive Director

Dr Ursula Ney

Non-Executive Director

Susan Clement Davies

Non-Executive Director

Dr Florian Reinaud

Non-Executive Director

PARTNERSHIPS

Scancell works actively with partners and collaborators in industry and academia to support its business strategy and to achieve its goals.